View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 18, 2022

Resverlogix expands Phase IIb apabetalone trial for Covid-19

Five more study centres in Brazil as well as a third Canadian site in Toronto, Ontario will become operational soon.

Resverlogix has expanded the Phase IIb clinical trial for analysing apabetalone (RVX-208) as a potential oral Covid-19 therapy to Brazil.

Apart from the first site launched in Brazil, the company initiated a second trial centre in Calgary city in the Canadian province of Alberta. 

Five more study centres in Brazil as well as a third Canadian site in Toronto, Ontario will become operational soon.

A small-molecule treatment candidate, apabetalone has an epigenetic mechanism of action. 

This bromodomain (BD2) selective bromodomain and extra-terminal (BET) inhibitor acts by modulating disease-causing gene expression to prevent and treat disease progression.

The open-label, randomised Phase IIb trial will analyse the safety and efficacy of apabetalone to potentially treat Covid-19. 

In the trial, subjects will be given either oral, twice-daily doses of apabetalone or standard of care alone. 

The company expects to enrol 100 patients in the coming weeks at various study centres in Brazil and Canada.

A variation in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement will be the primary outcome measure of trial.

The WHO Ordinal Scale for Clinical Improvement is a standardised approach of evaluating the severity of Covid-19 on an eight-point scale. 

Assessing the impact of apabetalone on biomarkers of inflammation will be included as the trial’s secondary endpoints.

Resverlogix president and CEO Donald McCaffrey said: “We are excited to be collaborating with Brazil on our Phase IIb clinical study, as part of our active and ongoing work with hospitals and ministries globally, to enrol and dose patients in our Covid-19 clinical trials.

“In consultation with Health Canada, we’ve updated our study protocol to account for the new variants, which could positively enhance the swiftness of patient enrolment.”

In January this year, the company commenced participant enrolment and dosing in the Phase IIb trial of apabetalone for Covid-19 in Canada.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy